AngioSoma (OTCQB:SOAN) is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments related to pharmaceutical or endovascular interventions. Our “end to end” solution will provide interventional radiologists, cardiologists, and internal medicine physicians with both pharmaceutical and or endovascular interventional options prior to infarction or critical limb ischemic events, stabilizing or reversing the atherosclerotic disease.
For pharmaceutical stabilization, our Liprostin™ product for treatment of peripheral artery disease (“PAD”) completed preliminary U.S. Food and Drug Administration (“FDA”) required Phase I and Phase II clinical trials successfully and is entering Phase III prior to approval. Our AngioSoma Research, Inc. subsidiary also owns the OmniCath I & II plaque debulking and vessel remodeling atherectomy catheterwhich will further support the stabilization of patients experiencing infarction or critical limb ischemic symptoms.
For long term preventative measures, our Transdermal PGE-1 Patch will provide ongoing treatment for chronic cardiovascular disease by delivery of PGE-1 or Liprostin™ through the skin.In all, we have a robust product pipeline from 20+ years of research and development, with existing patents, provisional patents, formulations, and trademarks from previously successful products.
AngioSoma Research, Inc. (Texas)
This was the subsidiary with all the intellectual property (“IP”) that was purchased in June 2016 which was a precursor to First Titan Inc. renaming itself to AngioSoma, Inc.